Drug Approval | June 26, 2026
FDA expands Pfizer’s IBRANCE use in HER2-positive breast cancer
Backed by Phase 3 trial showing 24% lower risk of progression
Backed by Phase 3 trial showing 24% lower risk of progression
The company emphasized that its mRNA system is built on three pillars—mRNA science, delivery science, and manufacturing processes
Company secures 7th position nationwide in India's Great Mid-size Workplaces 2026, reinforcing its people-first culture as it marks 75 years of excellence
Nuvectis gains global rights outside select Asian markets for oncology and complement disease therapies, with Haisco eligible for milestone payments and royalties
National conference brings together 160+ experts from six states to advance blood quality and safety standards
34% of pharma firms have already deployed function-specific AI, with drug discovery, clinical trials, and medical writing emerging as key high-impact use cases
Partnership with MAMTA HIMC aims to boost awareness, screening, HPV vaccination, and early detection of breast and cervical cancer in underserved communities
The company plans to use this funding to boost AI capabilities, expand vernacular content ecosystem, accelerate product development, and scale user acquisition across Tier 2 and Tier 3 markets
Innovative start-up award recognizes LIBERTY as a highly innovative, ground-breaking product with potentially wide range and/or substantial benefit
As competition intensifies in the obesity treatment market, a next-generation therapy may be in development.
Subscribe To Our Newsletter & Stay Updated
